Hims & Hers Health, Inc. Class A Common Stock (HIMS)
25.99
-2.00 (-7.15%)
NYSE · Last Trade: Apr 4th, 7:08 PM EDT
Detailed Quote
Previous Close
27.99
Open
26.30
Bid
25.55
Ask
25.60
Day's Range
23.97 - 27.09
52 Week Range
11.20 - 72.98
Volume
27,665,205
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
23,314,782
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its platform, marking a significant expansion beyond its previous focus on lower-cost alternatives to Novo Nordisk's Wegovy. This move positioned the company to tap into the growing demand for weight loss solutions and attract a broader customer base. The company added, "As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience."
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight loss, including versions (compounded) prescribed by Hims & Hers. There had been growing market demand for weight loss drugs in recent months, and they've evolved to be a significant driver of sales growth for manufacturers and distributors. The FDA's concerns could indicate tighter regulatory scrutiny, which restricts the ability of suppliers like Hims & Hers to get the affected versions to consumers.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 9.4%. This performance was disappointing since the S&P 500 held its ground.
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs introduces RKLX and HIMZ, two 2X leveraged single-stock ETFs designed to provide amplified exposure to Rocket Lab USA, Inc. (NASDAQ: RKLB) and Hims & Hers Health Inc. (NYSE: HIMS). These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.
